Berlex' Angeliq Approved, Will Launch In Mid-2006
This article was originally published in The Pink Sheet Daily
Executive Summary
The hormone therapy launch will be delayed to allow for physician education and to give the company time to consider internal resource issues as well as near-term pipeline opportunities, Berlex said.
You may also be interested in...
Berlex’ Yaz Receives Another “Approvable” Letter
Despite the setback, the firm continues to expect FDA approval for the low-dose oral contraceptive in the first quarter of 2006.
Berlex’ Yaz Receives Another “Approvable” Letter
Despite the setback, the firm continues to expect FDA approval for the low-dose oral contraceptive in the first quarter of 2006.
Berlex Climara Pro Gains Osteoporosis Prevention Indication
Berlex also updates labeling for the hormone replacement therapy to include new class labeling recommended by FDA.